araag2/HINT huggingface dataset:
Clinical trial NCT00676780 (phase 2, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: polyphenon e (egcg)
SMILES: OC1=CC(O)=C2C[C@@H](OC(=O)C3=CC(O)=C(O)C(O)=C3)[C@H](OC2=C1)C1=CC(O)=C(O)C(O)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  recent biopsy positive for prostate cancer

          -  scheduled for prostatectomy

          -  must be able to swallow capsules

          -  Palpable mass by digital rectal examination (DRE)

          -  Ability to give informed consent and willingness to adhere to study protocol

          -  Age ≥ 18 years and less than 75

        Exclusion Criteria:

          -  abnormal liver function

          -  Prior hormonal or surgical therapy for prostate cancer

          -  Liver or kidney problems that would interfere with metabolism of study drug

          -  Any condition that would hamper informed consent or ability to comply with study
             protocol

          -  Participation in another research study in the last three months

          -  Known malignancy at any site other than prostate

          -  Recent consumption of green tea (5 or more cups per day, within one week prior to
             biopsy)
Clinical trial NCT00314353 (phase 2, status: terminated)
Conditions: colorectal neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: bevacizumab, oxaliplatin, capecitabine, irinotecan
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O
Reason stopped: 
    the study was closed early due to low enrollment and new information regarding the benefit of
    the study regimen.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Pathological diagnosis of colon or rectal cancer from either the colon or rectum or a
             metastatic site (beyond the colon or rectum)

          -  Evidence of adequate organ function (such as liver, kidneys, etc.)

        Exclusion Criteria:

          -  Diagnosis of anal cancer

          -  Patients who are candidates for surgery

          -  Patients who have received previous treatments

          -  Pregnant or lactating women

          -  History of chronic disease(s) or other serious medical conditions
Clinical trial NCT01852019 (phase 2, status: completed)
Conditions: coronary artery disease
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: cangrelor, prasugrel
SMILES: CSCCNC1=C2N=CN([C@@H]3O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC(SCCC(F)(F)F)=N1, CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=CC=CC=C2F)S1
Eligibility criteria:

        Inclusion Criteria:

          1. greater than / equal to 18 and less than 75 years of age

          2. stable coronary artery disease defined by the following criteria

               1. Previous myocardial infarction defined by admission to the hospital with
                  elevation of markers of injury or the presence of pathologic Q waves on at least
                  2 contiguous electrocardiogram (ECG) leads.

                  OR

               2. Previous revascularization by percutaneous coronary intervention (PCI) or
                  coronary artery bypass graft (CABG).

                  AND

               3. Treatment with aspirin (ASA) 81 mg daily.
Clinical trial NCT00601848 (phase 2, status: terminated)
Conditions: lung cancer, metastatic cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: chemotherapy, porfimer sodium
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Reason stopped: 
    poor accrual and change in standards of care
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed non-small cell lung cancer (NSCLC)

               -  Must have clinical and/or pathological evidence of pleural spread

               -  Primary tumor must be resectable as assessed by the attending thoracic surgeon

          -  Patients who have received or are currently receiving two-to-four courses of standard
             front-line chemotherapy are eligible

        PATIENT CHARACTERISTICS:

          -  Must be medically fit to tolerate surgery

          -  No CTCAE v3.0 grade III-IV elevations in liver transaminases

          -  Bilirubin ≤ 1.5 mg/dL

          -  No known HIV infection

          -  Not pregnant or nursing

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior treatment for NSCLC except pleurodesis or standard front-line chemotherapy

          -  No prior pemetrexed disodium chemotherapy

          -  No prior mantle radiotherapy

          -  No concurrent chemotherapy or radiotherapy during the active study treatment period

               -  Post-operative radiotherapy will be administered as clinically indicated
Clinical trial NCT01730768 (phase 2, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: aqw051, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of schizophrenia

          -  Symptomatically stable and currently treated with a stable regimen for at least 3
             (three) months prior to dosing with one of the following second generation of
             antipsychotics: risperidone, paliperidone, quetiapine, ziprasidone, aripiprazole.

          -  Specific cognitive impairment

          -  Smokers and non-smokers

        Exclusion Criteria:

          -  Current treatment with an anticholinergic or other agent known to adversely interfere
             with the cholinergic system, and/ or treatment with cholinesterase inhibitor within
             the last three (3) months prior to dosing.

          -  Current treatment with conventional antipsychotics (e.g fluphenazine, haloperidol) or
             clozapine.

          -  History of neuroleptic malignant syndrome.

          -  Diagnosis of substance abuse (other than nicotine) within the last month and alcohol
             or substance dependence (other than nicotine) within the last 6 months.

          -  Score 4 or 5 on the Suicidal Ideation item or any "yes" on the Suicidal Behavior item
             of the CSSR-S that is related to suicidal behavior occurring during the last 2 years

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT01726270 (phase 2, status: completed)
Conditions: lower urinary tract symptoms
ICD codes: N40.2, N40.3, N40.0, N40.1
Drugs: tamsulosin
SMILES: CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O
Eligibility criteria:

        Inclusion criteria:

          1. Men 18 years of age and older.

          2. Able to speak, read and understand English.

          3. Willing to participate in the study and voluntarily sign an informed consent document.

        Exclusion criteria:

        1. Subject or anyone in their household is currently employed by a marketing or marketing
        research company, and advertising agency or public relations firm, a pharmacy or
        pharmaceutical company, a manufacturer of medicines, a managed care or health insurance
        company as a healthcare professional or healthcare practice.
Clinical trial NCT00418613 (phase 2, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: mk633, comparator: placebo (unspecified)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Documented COPD defined by clinical history and spirometry, with symptoms including
             dyspnea, wheezing, chest tightness, cough, sputum production, or nocturnal awakening

          -  Male or postmenopausal females 40 -75 years of age

        Exclusion Criteria:

          -  Impaired renal function

          -  History of chronic liver disease or persistent liver function test (LFT) abnormalities

          -  History of recent cardiovascular clinical event

          -  Evidence of another clinically significant, active pulmonary disorder such as
             bronchiectasis or asthma
Clinical trial NCT01483014 (phase 2, status: completed)
Conditions: gastrointestinal stromal tumors
ICD codes: C49.A0, C49.A1, C49.A2, C49.A5, C49.A3, C49.A4, C49.A9
Drugs: imatinib mesylate
SMILES: CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  patients with age between 18 and 80 years

          -  diagnosis of GIST not previously treated

          -  Patients will be included in the protocol regardless of operability; in the case of an
             operable tumor, patients are eligible if, in the opinion of the surgeon, resection
             would be suboptimal, disfiguring or functionally disabling (i.e. incomplete resection
             or other which cold compromise severely the quality of life or other GI function)

        Exclusion criteria:

          -  presence of metastatic disease

          -  use of other antineoplastic treatment (chemotherapy, immunotherapy, radiotherapy)

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00265317 (phase 2, status: completed)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: erlotinib, sunitinib, erlotinib, placebo
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with locally advanced/metastatic non-small cell lung cancer

          -  Prior treatment with no more than 2 chemotherapy regimens including a platinum-based
             regimen

        Exclusion Criteria:

          -  Prior treatment with any receptor tyrosine kinase inhibitors, Vascular endothelial
             growth factor (VEGF) inhibitors or other angiogenic inhibitors

          -  History of or known brain metastases
Clinical trial NCT00266812 (phase 2, status: terminated)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: temozolomide and radiotherapy
SMILES: CN1N=NC2=C(N=CN2C1=O)C(N)=O
Reason stopped: 
    patient target could not be reached within the planned timeframe.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Prior histologic confirmation of non-small cell lung cancer (NSCLC).

          -  Optional: NSCLC histologic confirmation of metastasis of NSCLC.

          -  Presence of unidimensionally measurable disease in the brain.

          -  No previous or current malignancies at other sites with the exception of adequately
             treated in situ carcinoma of the cervix or basal and squamous carcinoma of the skin.

          -  Age: >18 years.

          -  Subjects must not have systemic disease that in the opinion of the investigator is in
             immediate need of chemotherapy

          -  Karnofsky Performance status >=70%.

          -  Absolute neutrophil count (ANC) >1,500/mm^3, platelets >100,000/mm^3, hemoglobin >8
             g/dL.

          -  Serum creatinine and bilirubin <1.5 times upper normal limit of testing laboratory.

          -  Serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase
             (SGPT) <3 times upper limit of testing laboratory.

          -  Palliative radiation therapy to thorax and bone or other organs (except brain) is
             acceptable.

          -  Prior neurosurgery >2 weeks from initiating treatment with temozolomide.

          -  Cortisone medication stable or decreasing within 2 weeks prior to initiating treatment
             with temozolomide.

          -  Patient is not pregnant or nursing and is advised and willing to use an effective
             method of contraception.

          -  Written informed consent.

        Exclusion Criteria:

          -  Chemotherapy or biologic therapy within four weeks prior to initiating therapy with
             temozolomide.

          -  Prior radiation therapy for brain <4 weeks from initiating therapy with temozolomide.

          -  Surgery within two weeks prior to temozolomide administration.

          -  Recursive Partitioning Analysis (RPA) class III

          -  Patients with a single brain metastasis amenable to radiosurgery of resection

          -  Known Human Immunodeficiency Virus (HIV) disease.

          -  Acute infection requiring intravenous antibiotics.

          -  Any reason making compliance to the protocol improbable.
Clinical trial NCT00704184 (phase 2, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: comparator: vaniprevir, comparator: pegylated-interferon (peg-ifn), comparator: ribavirin, comparator: placebo
SMILES: [H][C@@]1(CC)C[C@]1(N=C(O)[C@]1([H])C[C@]2([H])CN1C(=O)[C@@]([H])(N=C(O)OCC(C)(C)CCCCC1=C3CN(CC3=CC=C1)C(=O)O2)C(C)(C)C)C(O)=NS(=O)(=O)C1CC1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has chronic Genotype 1 Hepatitis C infection

        Exclusion Criteria:

          -  Subject has been previously treated for HCV

          -  Has Human Immunodeficiency Virus (HIV)

          -  Has Hepatitis B

          -  Has a history of clinically significant medical condition that may interfere with the
             study (e.g., stroke or chronic seizures or major neurological disorder) or is
             contraindicated for treatment with peg-IFN and Ribavirin
Clinical trial NCT00303823 (phase 2, status: completed)
Conditions: cervical cancer, cervical intraepithelial neoplasia grade 1, human papilloma virus infection
ICD codes: M50.20, M50.21, M50.30, M50.31, M50.80, M50.81, M50.90
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed cervical intraepithelial neoplasia 1 (CIN 1) AND oncogenic
             human papillomavirus (HPV) positivity

          -  At increased risk for developing cervical cancer due to >= 1 of the following criteria
             (documented 6-12 months ago)*:

               -  Positive oncogenic HPV on DNA hybrid capture

               -  Low-grade squamous intraepithelial lesion cytology

               -  Histopathologically documented CIN 1 on cervical biopsy [Note: *Patients must now
                  have current CIN 1 by histology or colposcopy AND HPV positivity]

          -  Cervical dysplasia by colposcopy OR positive biopsy

          -  No invasive cervical cancer or high-grade intraepithelial neoplasia on cervical biopsy
             or endocervical curettage

          -  ECOG performance status < 2

          -  Total bilirubin < 2 times upper limit of normal (ULN)

          -  AST < 2 times ULN

          -  ALT normal

          -  Creatinine < 2.0 mg/dL

          -  Able and willing to return to clinic for study visits once every 4 weeks for the
             duration of the study

          -  No history of allergic reaction to tea or related dietary products

          -  No HIV positive patients (or AIDS/HIV-associated complex)

          -  No uncontrolled intercurrent illness including, but not limited to, any of the
             following:

               -  Ongoing or active infection other than HPV

               -  Symptomatic congestive heart failure

               -  Unstable angina pectoris

               -  Cardiac arrhythmia

               -  Psychiatric illness/social situation that would limit compliance with study
                  requirements

          -  No history of any cancer except nonmelanoma skin cancer

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No regular intake of 6 or more servings of tea per week within 1 month prior to study
             entry

          -  No treatment for genital condyloma within 30 days prior to study entry

          -  No prior pelvic irradiation

          -  No concurrent tea (green, black, or oolong) or tea-derived products

          -  No other concurrent investigational agents
Clinical trial NCT01465282 (phase 2, status: completed)
Conditions: psoriasis vulgaris
ICD codes: L40.0
Drugs: ct327 0.05%, ct327 0.1%, ct327 0.5%, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female subjects aged at least 18 years.

          -  Stable psoriasis vulgaris

        Exclusion Criteria:

          -  Subjects with guttate, erythrodermic, exfoliative or pustular psoriasis.
Clinical trial NCT00074438 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: methotrexate, rituximab, corticosteroids, placebo
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Eligibility criteria include, but are not limited to the following:

          -  Are between the ages of 18 and 80 years.

          -  Have been diagnosed with rheumatoid arthritis for at least 6 months.

          -  Have failed treatment (lack of efficacy) with at least 1 but no more than 5
             disease-modifying anti-rheumatic drugs or biologics (other than methotrexate).
Clinical trial NCT00184002 (phase 2, status: completed)
Conditions: non-hodgkin's lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: doxorubicin, rituxan, cyclophosphamide, vincristine and prednisone
SMILES: CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Pathologic diagnosis of Non-Hodgkin's lymphoma of B-cell origin: follicular large
             cell, diffuse large cell (including all B-cell variants), Burkitt or Burkitt-like
             lymphoma

          -  All stages of disease

          -  Measurable or evaluable tumor parameter(s)

          -  Age greater than 17 years old

          -  Karnofsky performance status greater or equal to 50%

          -  AGC greater or equal to 1.0; platelets greater or equal to 75,000(unless abnormal
             because of lymphoma)

          -  Bilirubin less or equal to 2.0; SGOT less or equal to 3 times upper limit of normal
             (unless abnormal because of lymphoma)

          -  Creatinine less or equal to 2.0 or creatinine clearance greater or equal to 60 ml/min
             (unless abnormal because of lymphoma)

          -  LVEF greater or equal to 45%

          -  Concurrent RT with or without steroids for emergency conditions secondary to lymphoma
             (i.e., CNS tumor, cord compression)are permitted

          -  Men and women of childbearing potential must agree to use adequate birth control for
             the duration of the therapy and for 3 months after completion of therapy

          -  Signed informed consent

        Exclusion Criteria:

          -  Prior systemic cytotoxic therapy or RT for lymphoma

          -  Second active tumor, other than non-melanomatous skin ca and in-situ cervical cancer

          -  HIV seropositive

          -  Primary CNS lymphoma

          -  Pregnant or nursing women

          -  Unable to comply with the requirements of the protocol, or unable to provide adequate
             informed consent, in the opinion of the PI
Clinical trial NCT00668070 (phase 2, status: completed)
Conditions: non-alcoholic steatohepatitis
ICD codes: K75.81
Drugs: asp9831, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  NASH, histologically confirmed by a liver biopsy performed within 1 year prior to
             first dose and randomization

          -  Elevated serum ALT levels

        Exclusion Criteria:

          -  Hepatic cirrhosis

          -  Other known cause of liver disease

          -  Uncontrolled diabetes mellitis type 2, i.e. HbA1c > 8.5%

          -  Positive history of tuberculosis or a positive PPD skin test which is not explained by
             previous BCG vaccination

          -  History of excessive alcohol abuse within 5 years prior to screening or a current
             average alcohol intake of more than 20 g/day (2 units) for females or more than 30
             g/day (3 units) for males

          -  Subject has used drugs associated with steatohepatitis within 6 months prior to
             screening (corticosteroids, high dose estrogens, methotrexate, amiodarone, anti-HIV
             drugs, tamoxifen)
Clinical trial NCT00667589 (phase 2, status: terminated)
Conditions: hand-foot skin reaction, rash
ICD codes: D72.823, F43.0, L43.2, R50.84, T80.92XS, F43.9, T80.92XA, R21, D72.12
Drugs: urea 40% cream, fluocinonide 0.05% cream, tazarotene 0.1% cream, bland emollient cream (udderly smooth® udder cream)
SMILES: NC(N)=O, [H][C@@]12C[C@@]3([H])[C@]4([H])C[C@]([H])(F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COC(C)=O, CCOC(=O)C1=CN=C(C=C1)C#CC1=CC2=C(SCCC2(C)C)C=C1
Reason stopped: 
    study was halted due to poor subject accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients receiving sorafenib as monotherapy or in combination if other agents are not
             known to cause HFSR.

          -  Subjects must be 18 years or older.

          -  Patients must provide written informed consent to participate in the study.

          -  Women of childbearing potential and men must be willing to use an effective method of
             contraception while participating in this study and for at least two weeks after
             completing treatment in the study.

          -  Women in this study need to have a negative urine pregnancy test before starting study
             medications.

        Exclusion Criteria:

          -  Patients simultaneously taking another anti-cancer agent or combination of anti-cancer
             agents known to cause hand foot syndrome (pegylated doxorubicin, 5-fluorouracil,
             cytarabine).

          -  Patients with an active dermatological condition due to previous chemotherapy or
             biologic therapy affecting the hands.

          -  Patients with pre-existing dermatological condition affecting the hands or feet.

          -  Women who have a positive pregnancy test or are lactating.